Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/182344
Title: | Peripheral T-cell lymphoma: Molecular profiling recognizes subclasses and identifies prognostic markers |
Author: | Rodríguez, Marta Alonso Alonso, Ruth Tomás Roca, Laura Rodríguez Pinilla, Socorro María Manso, Rebeca Cereceda, Laura Borregón, Jennifer Villaescusa, Teresa Cordoba, Raúl Sánchez Beato, Margarita Fernández Miranda, Ismael Betancor, Isabel Barcena, Carmen García, Juan F. Mollejo, Manuela García Cosio, Mónica Martín Acosta, Paloma Climent, Fina Caballero, Dolores Fuente, Lorena de la Minguez, Pablo Kessler, Linda Scholz, Catherine Gualberto, Antonio Mondejar, Rufino Piris, Miguel A. |
Keywords: | Limfomes Pronòstic mèdic Lymphomas Prognosis |
Issue Date: | 28-Dec-2021 |
Publisher: | American Society of Hematology |
Abstract: | Peripheral T-cell lymphoma (PTCL) is a clinically aggressive disease, with a poor response to therapy and a low overall survival rate of approximately 30% after 5 years. We have analyzed a series of 105 cases with a diagnosis of PTCL using a customized NanoString platform (NanoString Technologies, Seattle, WA) that includes 208 genes associated with T-cell differentiation, oncogenes and tumor suppressor genes, deregulated pathways, and stromal cell subpopulations. A comparative analysis of the various histological types of PTCL (angioimmunoblastic T-cell lymphoma [AITL]; PTCL with T follicular helper [TFH] phenotype; PTCL not otherwise specified [NOS]) showed that specific sets of genes were associated with each of the diagnoses. These included TFH markers, cytotoxic markers, and genes whose expression was a surrogate for specific cellular subpopulations, including follicular dendritic cells, mast cells, and genes belonging to precise survival (NF-κB) and other pathways. Furthermore, the mutational profile was analyzed using a custom panel that targeted 62 genes in 76 cases distributed in AITL, PTCL-TFH, and PTCL-NOS. The main differences among the 3 nodal PTCL classes involved the RHOAG17V mutations (P < .0001), which were approximately twice as frequent in AITL (34.09%) as in PTCL-TFH (16.66%) cases but were not detected in PTCL-NOS. A multivariate analysis identified gene sets that allowed the series of cases to be stratified into different risk groups. This study supports and validates the current division of PTCL into these 3 categories, identifies sets of markers that can be used for a more precise diagnosis, and recognizes the expression of B-cell genes as an IPI-independent prognostic factor for AITL. |
Note: | Reproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2021005171 |
It is part of: | Blood Advances, 2021, vol. 5, num. 24, p. 5588-5598 |
URI: | http://hdl.handle.net/2445/182344 |
Related resource: | https://doi.org/10.1182/bloodadvances.2021005171 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
advancesadv2021005171.pdf | 2.28 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License